Navigation Links
Elevation Pharmaceuticals Presents Positive Phase 2a Results in COPD Patients at the European Respiratory Society Annual Congress
Date:9/26/2011

SAN DIEGO, Sept. 26, 2011 /PRNewswire/ -- Elevation Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of new aerosol therapies for patients with respiratory diseases, announced today that it presented positive results from a Phase 2a study of EP-101 in patients with moderate to severe chronic obstructive pulmonary disease (COPD), a large and growing disease characterized by significant unmet clinical needs, at the annual meeting of the European Respiratory Society (ERS). The results demonstrated a statistically significant and well-tolerated improvement in lung function over the 24-hour time period post dosing for EP-101 versus placebo. EP-101 is a proprietary inhalation solution formulation of glycopyrrolate, a long-acting muscarinic antagonist (LAMA), delivered by an optimized, Investigational eFlow® Nebulizer System (PARI Pharma GmbH).  

The randomized, double blind, placebo controlled, cross-over, dose-ranging study evaluated the dose response, efficacy, safety and tolerability of single doses of EP-101 in 42 patients with moderate to severe COPD.  Following a single administration of one of several doses or placebo, all doses achieved a rapid onset of action (five minutes), short treatment time (two minutes), and a robust magnitude of bronchodilation compared to placebo.  The bronchodilatory improvements as assessed by forced expiratory volume in one second (FEV1), a standard measure of lung function, 24 hours after dosing was dose-dependent, statistically significant (p<0.001) at all doses compared to placebo, and clinically meaningful at several doses compared to placebo.  Favorable efficacy trends were also seen in a number of other endpoints including sustained improvements in FEV1 over the entire 24-hour period, demonstrating the potential for once-daily dosing. Throughout the study period, EP-101 was well tolerated at all doses with a comparable safety profile to placebo.

"The posit
'/>"/>

SOURCE Elevation Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Inspire MD Announce the MASTER (MGUARD for Acute ST Elevation Reperfusion) Randomized Trial in TCT2010. Study Chairman Will be Dr. Gregg Stone
2. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment in Zerenex™ (Ferric Citrate) Phase 3 Long-Term Study
3. Anadys Pharmaceuticals Updates Its Presentation Date at the Stifel Nicolaus Healthcare Conference
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Auxilium Pharmaceuticals, Inc. Announces 17 Month XIAFLEX® Safety Update
6. Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
7. Idenix Pharmaceuticals to Present at Three Upcoming Investor Conferences
8. Auxilium Pharmaceuticals to Present at the Morgan Stanley 2011 Healthcare Conference
9. Questcor Pharmaceuticals to Present at Upcoming Investor Conferences in September
10. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
11. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... DTS Language Services, Inc . is pleased to ... Science organizations who need document translations. Clients will now ... documents in advance with a selection of nearly 50 life ... a critical factor in clinical and scientific fields, and decrease ...
(Date:1/14/2014)... Date: Friday, April 11, 2014 , Time: ... 1360 Almshouse Road, Warrington, Pa. , Details: The ... to finding a cure for hepatitis B and improving the ... annual Crystal Ball on Friday, April 11 at Warrington Country ...
(Date:1/14/2014)... January 14, 2014 EquitiesIQ, a leading ... (OTCQB: ALQA). Alliqua is an emerging biomedical company acquiring, ... wound care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... a seasoned management team and Board, which launched the ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... Wis. - Gov. Jim Doyle announced Thursday his veto ... human cloning in Wisconsin. , ,The bill would outlaw not ... therapeutic or research cloning, in which an embryo is created ... of harvesting stem cells during the first several days of ...
... the central power station, the phonograph and recorded 1,000 patents, ... cost him millions of dollars and was dubbed Edisons Folly ... Apple Computers, the very company he helped to create. Dean ... of 150 patents, jokes that his biggest failure is that ...
... has completed a public deployment of PV.Web for ... GIS (geographic information systems) maps through the " Land ... , ,Built on ESRI's ArcIMS technology, anyone with a ... on both spatial and non-spatial land information, including transportation ...
Cached Biology Technology:Doyle vetoes cloning ban 2Embracing failure is a necessary step for successful entrepreneurs 2Embracing failure is a necessary step for successful entrepreneurs 3
(Date:4/17/2014)... Razzari of the nergie Matriaux Tlcommunications Research Centre ... John R. Evans Leaders Fund of the Canada ... state-of-the-art biotech and nanophotonics equipment. To this funding ... de l,Enseignement suprieur, de la Recherche, de la ... laboratories will help us develop new approaches for ...
(Date:4/17/2014)... Kansas State University engineer has developed a patented ... improvised explosive devices. The same technique could help ... Steven M. and Kay L. Theede chair in ... engineering, and his research team have created a ... in car trunks. The distance detection method ...
(Date:4/17/2014)... This news release is available in German . ... fails to pay the protection money demanded of him, he ... are seldom required, however, as fear of the consequences is ... is observed in parasitic birds, which lay their eggs in ... egg out, the brood parasites take their revenge by destroying ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3
... Most parents of teenage children have experienced frustration at their ... this ubiquitous technology could be used to save lives? At ... nation of Tanzania, a country where few have landlines but ... Joyce Nyoni is trying to do. amfAR, The Foundation ...
... Queen Mary, University of London have discovered how changes to ... a viral infection which is devastating frog populations across the ... being struck down by a foreign virus which is estimated ... UK each year. When it strikes garden ponds, the surrounding ...
... Antonio G. Pisabarro (Professor of Microbiology) as well as ... Genetic and Microbiology Group at the Public University of ... the sequencing of the genome of the Postia ... American National Academy of Sciences, scientific journal ( PNAS ...
Cached Biology News:Cutting-edge amfAR grants fight HIV/AIDS in the lab and on the phone 2Cutting-edge amfAR grants fight HIV/AIDS in the lab and on the phone 3Cutting-edge amfAR grants fight HIV/AIDS in the lab and on the phone 4Cutting-edge amfAR grants fight HIV/AIDS in the lab and on the phone 5Cutting-edge amfAR grants fight HIV/AIDS in the lab and on the phone 6Cutting-edge amfAR grants fight HIV/AIDS in the lab and on the phone 7Cutting-edge amfAR grants fight HIV/AIDS in the lab and on the phone 8Frog's immune system is key in fight against killer virus 2Genome sequencing of fungus with biotechnological applications 2Genome sequencing of fungus with biotechnological applications 3
Mouse monoclonal [3G8] to MDMA ( Abpromise for all tested applications)....
Fluorescein isothiocyanate (FITC) mouse anti-human IFN-alpha2 50 ug...
Dog polyclonal to Porcine Pancreatic Islets of Langerhans Cells ( Abpromise for all tested applications). Antigen: Tissue / cell preparation (Pig): Sonicated crude membrane fraction of porcine p...
Anti-human C5/C5b, Clone 568, Monoclonal Antibody...
Biology Products: